Clinical Trial Update: Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) [Phase 2]

View source ↗

Summary

Phase 2 trial investigating a glycine uptake inhibitor as adjuvant treatment for negative symptoms in schizophrenia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MK-8435-001 (glycine uptake inhibitor)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2016-12-13